SPX3,693.23-64.76 -1.72%
DIA295.86-4.66 -1.55%
IXIC10,867.93-198.88 -1.80%

Berenberg Initiates Coverage On Blueprint Medicines with Buy Rating, Announces Price Target of $90

Berenberg analyst Zhiqiang Shu initiates coverage on Blueprint Medicines (NASDAQ:BPMC) with a Buy rating and announces Price Target of $90.

Benzinga · 09/14/2022 06:45
Berenberg analyst Zhiqiang Shu initiates coverage on Blueprint Medicines (NASDAQ:BPMC) with a Buy rating and announces Price Target of $90.